Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$7,856 Mln
P/E Ratio
--
P/B Ratio
1.51
Industry P/E
--
Debt to Equity
0.08
ROE
-0.15 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-0.14
CFO
$-3,859.32 Mln
EBITDA
$-2,895.93 Mln
Net Profit
$-2,895.83 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Roivant Sciences (ROIV)
| -5.41 | 6.77 | 0.45 | 1.45 | 44.10 | -- | -- |
|
BSE Sensex*
| 2.63 | 3.74 | 5.81 | 8.92 | 11.77 | 20.12 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
Roivant Sciences (ROIV)
| 40.55 | -20.73 | -0.88 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines... and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom. Address: 50 Broadway, London, United Kingdom, SW1H 0DB Read more
CEO & Director
Mr. Matthew Gline
CEO & Director
Mr. Matthew Gline
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Roivant Sciences Ltd (ROIV) stood at $ 5,934 Mln as on 31-Dec-24
The share price of Roivant Sciences Ltd (ROIV) is $11.19 (NASDAQ) as of 28-Apr-2025 16:22 EDT. Roivant Sciences Ltd (ROIV) has given a return of 44.1% in the last 3 years.
Roivant Sciences Ltd (ROIV) has a market capitalisation of $ 7,856 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Roivant Sciences Ltd (ROIV) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Roivant Sciences Ltd (ROIV) and enter the required number of quantities and click on buy to purchase the shares of Roivant Sciences Ltd (ROIV).
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom. Address: 50 Broadway, London, United Kingdom, SW1H 0DB
The CEO & director of Mr. Matthew Gline. is Roivant Sciences Ltd (ROIV), and CFO & Sr. VP is Mr. Matthew Gline.
There is no promoter pledging in Roivant Sciences Ltd (ROIV).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Roivant Sciences Ltd (ROIV) | Ratios |
|---|---|
|
Return on equity(%)
|
1.01
|
|
Operating margin(%)
|
4817.39
|
|
Net Margin(%)
|
-119.54
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Roivant Sciences Ltd (ROIV) was $0 Mln.
$0.18
(
